Clinical Study
Influence of APOE Genotype on Alzheimer’s Disease CSF Biomarkers in a Spanish Population
Table 6
Influence of CSF AD variables on progression to AD.
| | | Frequency of progression to AD | Crude odds ratio (95% CI) | Adjusted odds ratio (95% CI) |
| | Aβ protein levels | | | | | ≤710 (pg/mL) | 60.0% (9/15) | 10.8 (2.7–43.) | 3.8 (0.6–22.1) | | ≥711 (pg/mL) | 12.2% (5/41) | 1 | 1 | | T-tau protein levels | | | | | ≤421 (pg/mL) | 71.4% (10/14) | 1 | 1 | | ≥422 (pg/mL) | 9.5% (4/42) | 23.7 (5.0–112.0) | 13.9 (2.2–87.0) | | p-tau protein levels | | | | | ≤63 (pg/mL) | 11.6% (5/43) | 1 | 1 | | ≥64 (pg/mL) | 69.2% (9/13) | 17.1 (3.8–76.8) | 10.34 (1.84–58.14) | | T-tau/Aβ ratio | | | | | <0.54 | 9.5% (4/42) | 1 | 1 | | ≥0.54 | 71.4% (10/14) | 23.75 (5.0–112.0) | 19.83 (2.64–148.56) | | p-tau/Aβ ratio | | | | | <0.10 | 9.5% (4/42) | 1 | 1 | | ≥0.10 | 71.4% (10/14) | 23.75 (5.0–112.0) | 13.91 (2.18–88.74) |
|
|
